Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The investigators design a phase IIB clinical study to explore the efficacy and safety of
Donafenib combined with TACE as adjuvant therapy of patients with hepatocellular carcinoma at
a high risk of recurrence after radical resection.